



**Vita Life Sciences Limited**

ACN 003 190 421

ABN 35 003 190 421

**Corporate Office**

Suite 802, Level 8,  
1-5 Chalmers Crescent  
Mascot NSW 2020  
Australia

T: 61 2 9545 2633

F: 61 2 9545 1311

[vitalifesciences.com](http://vitalifesciences.com)

22 May 2025

Market Announcements  
Australian Securities Exchange Ltd  
20 Bridge Street  
Sydney, NSW 2000

Dear Sir/ Madam,

**RESULTS OF VITA LIFE SCIENCES LTD'S 2025 ANNUAL GENERAL MEETING-22 MAY 2025**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that all the resolutions put forth to the shareholders were duly passed.

The details of the resolutions and proxies received in respect of each resolution are set out in the summary attached.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Chin L Khoo', is written over a light blue horizontal line.

Chin L Khoo  
Company Secretary  
Email: [enquiries@vitalifesciences.com.au](mailto:enquiries@vitalifesciences.com.au)

# Disclosure of Proxy Votes

Vita Life Sciences Limited  
Annual General Meeting  
Thursday, 22 May 2025



**AUTOMIC**

**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Remuneration Report	P	26,108,186	19,724,424 75.55%	85,222 0.33%	818,348	6,298,540 24.12%	26,022,964 99.67%	85,222 0.33%	848,348	-
2 Re-election of Director- Mr Henry Townsing	P	35,530,677	29,183,993 82.14%	48,144 0.14%	4,500	6,298,540 17.73%	35,553,717 99.86%	48,144 0.14%	19,770	Carried
3 Aggregate Annual Remuneration Payable to Non-Executive Directors be increased to maximum of \$300,000 from Year 2026	P	26,509,484	20,121,222 75.90%	89,722 0.34%	590,000	6,298,540 23.76%	26,419,762 99.55%	119,722 0.45%	631,184	Carried
4 Share Buy-Back	P	35,534,677	13,279,794 37.37%	32,843 0.09%	500	22,222,040 62.54%	35,558,288 99.91%	32,843 0.09%	30,500	Carried

